Target intelligence / Profile preview

Pseudomonas aeruginosa biofilm formation and motility

Molecular classification
Transcription factor, Enzyme, Receptor, Other
01

Overview

Pseudomonas aeruginosa biofilm formation and motility represent critical virulence mechanisms that enable this opportunistic pathogen to establish chronic, antibiotic-resistant infections. Biofilms are structured communities of bacteria encased in a self-produced matrix of extracellular polymeric substances (EPS), which protects the microbes from host immune responses and antimicrobial agents (Source: Nature Reviews Microbiology, 2015). Motility, including swimming, swarming, and twitching, is essential for the initial stages of surface colonization and the subsequent dispersal of bacteria from mature biofilms (Source: Microbiology and Molecular Biology Reviews, 2011). These processes are tightly regulated by complex signaling networks, most notably quorum sensing (QS) systems and the secondary messenger cyclic-di-GMP (Source: Frontiers in Microbiology, 2019). Therapeutic strategies targeting these pathways aim to disarm the bacteria rather than kill them directly, potentially reducing the selective pressure for antibiotic resistance. Current research focuses on small molecule inhibitors of QS receptors like LasR and PqsR, as well as agents that degrade the biofilm matrix or modulate c-di-GMP levels to promote a transition from a sessile to a more vulnerable planktonic state (Source: Journal of Medicinal Chemistry, 2020).

Other names
Biofilm developmentBacterial motilityP. aeruginosa virulence factorsQuorum sensing-regulated phenotypes
02

Mechanism of action

Quorum sensing inhibition, c-di-GMP modulation, Extracellular polymeric substance (EPS) degradation, Iron metabolism interference, Type IV pili inhibition

03

Biological functions

Biofilm formationCell motilityQuorum sensingSignal transductionAdhesion
04

Disease associations

InfectionCystic fibrosisChronic wound infectionVentilator-associated pneumoniaUrinary tract infection
05

Safety considerations

Risk of promoting planktonic disseminationPotential impact on host microbiomeDevelopment of resistance to anti-virulence agentsLack of standardized clinical endpoints for biofilm eradication
06

Interacting drugs

Azithromycin

5 more in the full profile.

07

Biomarkers

Acyl-homoserine lactones (AHLs)Pseudomonas quinolone signal (PQS)Cyclic-di-GMP levelsAlginate production

Beyond the preview

Go deeper on Pseudomonas aeruginosa biofilm formation and motility.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pseudomonas aeruginosa biofilm formation and motility.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call